Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analyst predicts the global erythropoietin drugs market to grow steadily and project an impressive overall revenue of USD 10 billion by 2021. One of the primary drivers for this market is the increase in chronic kidney disease (CKD) and dialysis patient pool.
In terms of geography, EMEA accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The market will typically witness a relatively higher growth rate in countries such as the UK, Germany, Spain, France, and Italy. Also, the induction of erythropoietin biosimilars will support the sale of erythropoietin drugs in the region. Moreover, favourable and flexible healthcare regulations in several countries across the globe will further propel the growth of the global erythropoietin drugs market in the coming years.
The global erythropoietin drugs market is moderately fragmented due to the presence of international and regional vendors. These vendors exhibit strong R&D capabilities and have established distribution systems in place. Occasional spurts of competition have also been witnessed from the local manufacturers present in various countries. The entry prospect of new players is medium to low, considering the slow growth and complex nature of the market.
Leading vendors in the market are
Other prominent vendors in the erythropoietin drugs market include Ahua Pharmaceutical, 3SBio, BIOSIDUS, Biocon, Boehringer Ingelheim, Chugai Pharmaceutical, Celltrion, Intas Pharmaceuticals, Cipla, DAICHI SANKYO, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Dragon Pharma, Huaxin High Biotechnology, JCR Pharmaceuticals, Shanghai Kehua Bio-Engineering, LG Life Science, Novartis, Pfizer, Sandoz International, Shenyang Sunshine Pharmaceutical, Shenzhen Sai Bao Er Bio-Pharmaceutical, Sihuan Pharmaceutical, STADA, Uni-Bio Science, and Wanbang Biochemical Pharmaceuticals.
During 2016, the retail pharmacies segment dominated the erythropoietin drugs market and accounted for a major part of the overall market share. The ability of retail pharmacies to provide a large customer base for biosimilars coupled with the requirement from anemic patients for EPO drugs as a maintenance therapy is the key contributor to the dominance of this segment in the global market.
Chemotherapy targets fast-dividing cancer cells and the healthy cells in the body. Cells in the bone marrow are highly sensitive to chemotherapy, which results in the decreased production of red blood cells in the body. Erythropoietin binds to the red blood cell progenitor's surface receptor in the bone marrow and stimulates proliferation, maturation, and differentiation of cells. This helps correct anemia in cancer patients.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Biosimilars: Overview
PART 06: Erythropoietin: An overview
PART 07: Market landscape
PART 08: Pipeline portfolio
PART 09: Marketed products portfolio
PART 10: Market segmentation by end-user
PART 11: Market segmentation by application
PART 12: Market segmentation by product
PART 13: Geographical segmentation
PART 14: Market drivers
PART 15: Impact of drivers
PART 16: Market challenges
PART 17: Impact of drivers and challenges
PART 18: Market trends
PART 19: Vendor landscape
PART 20: Key vendor analysis
PART 21: Appendix
Tags: chemotherapy drugs, epo drug, diagnostic imaging services, chemotherapy treatment, medical devices market analysis, healthcare market analysis,
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.